Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard therapy for lupus nephritis is more efficacious ...

美时（1795）20日宣布，美国FDA已接受 Voclosporin 软胶囊的潜在首家简化新药申请（ANDA），原厂药物为 AuriniaPharmaceuticals Inc. 的 Lupkynis®。Lupkynis® 是第一个也是唯一一个获 FDA 批准用于治疗狼疮肾炎（lu ...

美时(1795)今(20)日宣布，美国食品药品监督管理局(FDA)已接受Voclosporin软胶囊的潜在首家简化新药申请(ANDA)，原厂药物为Aurinia Pharmaceuticals Inc.的Lupkynis。Lupkynis是第一个也是唯一一个获FDA批准用于治疗 ...

Cabaletta’s new data slice for its investigational CD19-CAR T cell therapy shows “robust benefit” for patients with lupus and ...

Gazyva/Gazyvaro (obinutuzumab) was found to significantly improve complete renal response in lupus nephritis patients, ...

Aurinia can still see growth in product revenues from Lupkynis and has a chance to show that AUR200 has some value in 2025.

More than 50% of patients with systemic lupus erythematosus (SLE) develop lupus nephritis (LN) during the disease, which may ...

Roche’s Gazyva/Gazyvaro (obinutuzumab) has demonstrated superiority over standard therapy in patients with active lupus ...

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...

Obinutuzumab B-cell depleting therapy is more effective than standard care in treating patients with active proliferative lupus nephritis.

The U.S. Food and Drug Administration (FDA) has granted fast track status to ADI-001, Adicet Bio ’s CAR T-cell therapy for ...

The FDA has granted Fast Track designation to ADI-001 for the treatment of refractory systemic lupus erythematosus with extrarenal involvement.